Update on the Diagnosis and Treatment of Hepatocellular Carcinoma.

Autor:	Ferrante ND; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Biostatistics, Epidemiology, and Informatics; Center for Clinical Epidemiology and Biostatistics; Center for Pharmacoepidemiology Research and Training; Perelman School of Medicine; University of Pennsylvania; Philadelphia; Pennsylvania., Pillai A; Division of Gastroenterology and Hepatology, University of Chicago Medicine, Chicago, Illinois., Singal AG; Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas.
Jazyk:	angličtina
Zdroj:	Gastroenterology & hepatology [Gastroenterol Hepatol (N Y)] 2020 Oct; Vol. 16 (10), pp. 506-516.
Abstrakt:	Hepatocellular carcinoma (HCC) is the fourth-leading cause of cancer-related mortality worldwide and the fastest-rising cause of cancer-related death in the United States. Given the strong association between tumor stage and prognosis, HCC surveillance is recommended in high-risk patients, including patients with cirrhosis from any etiology. The diagnosis can be made based on characteristic imaging findings, with histologic confirmation primarily reserved for patients with atypical imaging findings. Over the last 2 decades, the treatment landscape for HCC has experienced significant advances. Curative therapies, including liver transplantation and surgical resection, are available to patients with early-stage HCC; however, recent data have expanded the potentially eligible patient population. Locoregional therapies, including transarterial chemoembolization and transarterial radio-embolization, continue to be standard therapies for patients with intermediate-stage disease. The greatest advances have been observed for patients with advanced HCC, where there are now multiple first- and second-line options that can prolong survival by up to 2 years when used sequentially. The increasing complexity of HCC treatment options underlies the necessity for multidisciplinary care, which has been associated with increased survival. This article reviews data on best practices for early detection and diagnosis of HCC and the current status of treatment options. Competing Interests: Dr Singal has served on the advisory board or as a consultant for Bayer, Eisai, Exelixis, Bristol Myers Squibb, Genentech, Wako Diagnostics, Exact Sciences, Roche, and Glycotest. Dr Singal’s research is supported in part by NIH R01 CA212008 and R01 MD012565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The other authors have no relevant conflicts of interest to disclose. (Copyright © 2020, Gastro-Hep Communications, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu